中文名稱:化合物 Lanabecestat | 英文名稱:Lanabecestat |
CAS:1383982-64-6 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 98.55% | 產(chǎn)品類別: 抑制劑 |
貨號: TQ0238 |
Name | Lanabecestat |
Description | Lanabecestat (AZD3293) is a highly potent and highly permeable, orally active BACE1 inhibitor (Ki: 0.4 nM) that crosses the blood-brain barrier, Lanabecestat can be used for the study of neurological diseases like Alzheimer's disease. |
Cell Research | Cells are incubated with different Lanabecestat concentrations for 5 to 16?h, and the release of sAβPPβ, Aβ1-40, Aβ1-42, or sAβPPα into the medium is analyzed using kits. Cytotoxic effect of Lanabecestat is evaluated in the cell plates using cell proliferation/cytotoxicity kit. |
Animal Research | Female 7- to 14-week-old C57BL/6 mice (n=6 per treatment group and time point) receive a vehicle or Lanabecestat solution at 50, 100, or 200 μmol/kg (20, 41, or 82?mg/kg) as a single dose via oral gavage. Mice and guinea pigs are anesthetized 1.5, 2, 3, 4, 6, 8, 16, 24, or 48?h after the (last) administration of vehicle or drug and are then kept under isoflurane anesthesia. Cerebrospinal fluid (CSF) is aspirated from the cisterna magna, and plasma is isolated from blood collected by cardiac puncture into EDTA tubes. The animals are then sacrificed by decapitation, and the brains are dissected into hemispheres. |
In vitro | Lanabecestat 差異性地改變了 5xFAD 和 APP KI小鼠的小膠質(zhì)細(xì)胞蛋白水平[1]。 |
In vivo | Lanabecestat 治療(1 mg/kg;口服灌胃;每天一次;持續(xù) 3 周)能在 4-AP 細(xì)胞發(fā)生模型中增加了 Bace1-null 小鼠的爆發(fā)頻率[1]。 |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 80 mg/mL (193.92 mM), Sonication is recommended. |
Keywords | AZD-3293 | AZD 3293 | Lanabecestat | LY-3314814 | LY 3314814 |
Inhibitors Related | Loganin | Epiberberine | Aloeresin D | Phytic acid potassium | LY2886721 | NB-360 | Atabecestat | Auraptene | Verubecestat | DSS30 |
成立日期 | 2013-04-18 (12年) | 注冊資本 | 566.265100萬人民幣 |
員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
VIP1年
|
青島愷潤生物醫(yī)藥科技有限公司
|
2025-02-07 | |
詢價 |
VIP5年
|
山東沃德森生物科技有限公司
|
2025-02-12 | |
詢價 |
VIP3年
|
陜西締都新材料有限公司
|
2024-12-18 |